Kodiak Sciences Inc. (KOD) Presents at UBS Global Biopharma Conference 2026 TranscriptSeeking Alpha • Tuesday
Kodiak Sciences: Sticking With Hold As Optimistic Assumptions Are Already Priced InSeeking Alpha • 11/13/26
Kodiak Q3 Loss Wider Than Expected, Pipeline Development in FocusZacks Investment Research • 11/13/26
Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2026 Financial ResultsPRNewsWire • 11/12/26
Kodiak Sciences to Present Clinical Data Across All Three Late-Stage Programs at AAO 2026PRNewsWire • 10/07/26
A $32 Biotech Became a $90 Biotech Overnight. Is It Too Late to Buy Kodiak?24/7 Wall Street • 09/30/26
KOD Stock Soars 178% on Positive Wet AMD Data as BLA Filing NearsZacks Investment Research • 09/29/26
Kodiak Sciences Inc. (KOD) Discusses DAYBREAK Topline Data and Primary Endpoint Results TranscriptSeeking Alpha • 09/28/26
Kodiak Sciences soars as Zenkuda, tabirafusp-ted hit primary endpoints in phase III wet AMD trialProactive Investors • 09/28/26
Kodiak Sciences to Present Topline Results on September 28, 2026 from DAYBREAK Pivotal Phase 3 Study of Zenkuda and KSI-501 in Patients with Wet Age-Related Macular DegenerationPRNewsWire • 09/25/26
Kodiak's Q2 Loss Wider Than Expected, Pipeline Development in FocusZacks Investment Research • 08/14/26
Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2026 Financial ResultsPRNewsWire • 08/13/26